Sanofi's stock declines amid regulatory delays and market conditions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 Dec 25
Source: Coinmarketcap
Sanofi SA's stock price fell by 3.04% and hit a 20-day low, reflecting a challenging market environment.
This decline is attributed to the anticipated delay in the regulatory review process for tolebrutinib, which is expected to extend beyond the previously communicated target action date of December 28, 2025. This news comes amid a mixed market backdrop, with the Nasdaq-100 down 0.10% and the S&P 500 slightly up by 0.03%, suggesting sector rotation as investors reassess their positions.
The implications of this delay could affect Sanofi's market access strategies and overall positioning in the multiple sclerosis treatment landscape, particularly as the company navigates the complexities of regulatory approvals.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNY is 78.52 USD with a low forecast of 57.00 USD and a high forecast of 116.57 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 45.770
Low
57.00
Averages
78.52
High
116.57
Current: 45.770
Low
57.00
Averages
78.52
High
116.57
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
